Despite many promising leads, more than 120 drug treatments for Alzheimer’s disease have failed. But Cambridge-based biotech company Biogen revived hope on Tuesday with its announcement that it would seek Food and Drug Administration approval for a drug it abandoned earlier this year. Biogen’s experimental Alzheimer’s drug aducanumab targets beta-amyloid proteins that form plaque in the brain, which many scientists believe contributes to the debilitating disease. Investors and doctors considered Biogen’s drug the best hope...

Source: Wall Street Journal October 23, 2019 23:15 UTC